📰 Survival Data News
Survival Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Survival Data. Real-time updates on events, politics, business and more.
September 1, 2023
A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.
May 22, 2023
Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.
May 3, 2023
Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.
March 30, 2023
Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.
June 9, 2022
-- New analyses showing AYVAKIT® (avapritinib) significantly improved overall survival in advanced SM, when indirectly compared to real-world data for prior...
June 2, 2021
- Data from the IT-01 trial demonstrate the safety of INT230-6 (PORT-1) as both a monotherapy and in combination with checkpoint inhibitors in solid tumors - Survival data looks favorable compared to similar historical populations, balanced for prognostic factorsWestport, Connecticut--(Newsfile Corp. - June 2, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a ...
February 23, 2021
Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces 21-month follow-up data from the randomized phase I/II trial of ONCOS-102 in combination with standard of care chemotherapy in malignant pleural mesothelioma (MPM).